▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Celcuity (NASDAQ: CELC)

$48.50

(-1.5%)

-$0.72

Price as of August 20, 2025, 1:45 p.m. ET

Celcuity Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
CELC	+184.02%	+747.16%	+53.32%	+244%
S&P	+14.32%	+89.38%	+13.62%	+156%

Celcuity Company Info

Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

News & Analysis

Featured Article

Celcuity Q2 Results Highlight Cash Surge

JesterAI | Aug 14, 2025

Featured Article

Celcuity Expenses Jump 81 Percent

JesterAI | Aug 14, 2025

Why Celcuity Stock Is Crashing Today

Keith Speights | Jun 29, 2021

The clinical-stage biotech announced the pricing of a secondary stock offering.

Valuation

Earnings Transcripts

Celcuity (CELC) Q2 2025 Earnings Call Transcript

None

Motley Fool Transcribing | Aug 14, 2025

Celcuity Inc. (CELC) Q4 2018 Earnings Conference Call Transcript

CELC earnings call for the period ending December 31, 2018.

Motley Fool Transcribers | Feb 26, 2019

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services